Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review

Marlies Oosthoek,Lisa Vermunt,Arno de Wilde,Bram Bongers,Daniel Antwi-Berko,Philip Scheltens,Pieter van Bokhoven,Everard G. B. Vijverberg,Charlotte E. Teunissen
DOI: https://doi.org/10.1186/s13195-024-01456-1
2024-04-29
Alzheimer s Research & Therapy
Abstract:Clinical trials in Alzheimer's disease (AD) had high failure rates for several reasons, including the lack of biological endpoints. Fluid-based biomarkers may present a solution to measure biologically relevant endpoints. It is currently unclear to what extent fluid-based biomarkers are applied to support drug development.
neurosciences,clinical neurology
What problem does this paper attempt to address?